128 related articles for article (PubMed ID: 24854415)
1. The use of phase 2 interim analysis to expedite drug development decisions.
Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
[TBL] [Abstract][Full Text] [Related]
2. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
4. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
Hong S; Shi L
Stat Med; 2012 Apr; 31(9):831-43. PubMed ID: 22302442
[TBL] [Abstract][Full Text] [Related]
5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
6. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
Uozumi R; Hamada C
J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
[TBL] [Abstract][Full Text] [Related]
7. Tumor burden modeling versus progression-free survival for phase II decision making.
Kaiser LD
Clin Cancer Res; 2013 Jan; 19(2):314-9. PubMed ID: 23172885
[TBL] [Abstract][Full Text] [Related]
8. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Rufibach K; Heinzmann D; Monnet A
Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
[TBL] [Abstract][Full Text] [Related]
9. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
10. A two-stage patient enrichment adaptive design in phase II oncology trials.
Song JX
Contemp Clin Trials; 2014 Jan; 37(1):148-54. PubMed ID: 24342820
[TBL] [Abstract][Full Text] [Related]
11. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
12. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
13. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
14. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review.
Shimura M; Nomura S; Wakabayashi M; Maruo K; Gosho M
JAMA Netw Open; 2020 Jun; 3(6):e208633. PubMed ID: 32573709
[TBL] [Abstract][Full Text] [Related]
16. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
18. Evaluating futility of a binary clinical endpoint using early read-outs.
Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
[TBL] [Abstract][Full Text] [Related]
19. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
20. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]